CHICAGO, Oct. 8, 2026 – Pulse Infoframe, a leader in real-world evidence (RWE) generation and intelligence, today announced a strategic partnership with EVERSANA, a leading provider of technology enabled, modern commercialization services to the biopharmaceutical industry. Through the partnership, Pulse Infoframe will pair its proprietary RWE platform and established evidence-generation capabilities with EVERSANA’s end-to-end commercialization, market access and health economics and outcomes research (HEOR) expertise, creating a single, continuous evidence engine for pharmaceutical and medical device companies.
The partnership spans the full arc of evidence generation: global site-network and feasibility assessments, registry and natural history study design, and direct data capture from sites and patients, followed by HTA-grade reporting, global value dossiers, and reimbursement strategy. By designing studies to serve regulators, HTA bodies, and commercial teams alike, Pulse Infoframe and EVERSANA help clients carry a single evidence base from first patient enrolled through launch and beyond.
“Our platform was built to generate regulatory-grade evidence directly from sites and patients,” said Femida Gwadry-Sridhar (PhD), Chief Executive Officer, Pulse Infoframe. “Working with EVERSANA connects that evidence to the regulatory, reimbursement, and commercial decisions it needs to support, at global scale.”
The partnership offers pharmaceutical and medical device manufacturers a seamless solution for evidence generation from study design and global site-network assessments to sophisticated external control arm methods and Health Technology Assessment (HTA)-grade reporting. By uniting complementary strengths, the collaboration delivers compounding gains in efficiency, data quality, and global scale.
“Real-world evidence has never been more critical as pharmaceutical companies work to develop the best strategies to bring innovative therapies to patients,” said Mark Thierer, Chief Executive Officer, EVERSANA. “By pairing our deep commercial and health economics expertise with Pulse Infoframe’s robust registry expertise in complex conditions, including rare disease and oncology, we can bring unmatched solutions to customers to help improve market access.”
The partnership will be highlighted by Pulse Infoframe and EVERSANA at ISPOR Europe 2026, November 8-11 in Vienna, Austria.
About Pulse Infoframe
Pulse Infoframe is a leading real-world data and evidence generation partner that provides services to clients in the life sciences and healthcare sectors. The company owns and operates its real-world evidence platform, with expertise in registries, natural history studies, and the ability to generate regulatory-grade data directly from sites and patients.
About EVERSANA®
EVERSANA® is the leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com.
Media Contacts:
Femida Gwadry-Sridhar, BSc Pharm, MSc (Epi), PhD
Chief Executive Officer and Founder, Pulse Infoframe
Matt Braun
VP, Corporate Communications, EVERSANA
